Use of recombinant human DNase in a premature infant with recurrent atelectasis

Pediatrics International

Volumn 45, Issue 5, 2003, Pages 584-586

  Küpeli, Serhan ^a,b   Teksam, Özlem ^a   Dogru, Deniz ^a   Yurdakök, Murat ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

Atelectasis; Premature neonate; rhDNase

Indexed keywords

ACETYLCYSTEINE; AMPICILLIN; DEOXYRIBONUCLEASE; DEXAMETHASONE; ERYTHROMYCIN; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; NETILMICIN; RECOMBINANT HUMAN DEOXYRIBONUCLEASE; SALBUTAMOL; UNCLASSIFIED DRUG; VANCOMYCIN;

ANAMNESIS; APGAR SCORE; ARTICLE; ARTIFICIAL VENTILATION; ATELECTASIS; BIRTH WEIGHT; BLOOD CHEMISTRY; CASE REPORT; CESAREAN SECTION; EXPERIENCE; FEMALE; GESTATIONAL AGE; HOSPITAL DISCHARGE; HUMAN; LABORATORY TEST; LUNG DYSPLASIA; MEMBRANE RUPTURE; MUCUS; NEBULIZATION; NEWBORN; PATHOPHYSIOLOGY; PHYSICAL EXAMINATION; PLACENTA; PREMATURITY; PRIORITY JOURNAL; RECURRENT DISEASE; UMBILICAL CORD;

EID: 0242575962     PISSN: 13288067     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-200x.2003.t01-1-01791.x     Document Type: Article

References (12)

1. Merkus PJ, de Hoog M, van Gent R, de Jongste JC. DNase treatment for atelectasis in infants with severe respiratory syncytial virus bronchiolitis. Eur. Respir. J. 2001; 18: 734-7.
2. Hansen G, Hoffjan S, Mosler K, Schuster A. Effect of recombinant human DNase on alpha1-proteinase inhibitor function, an experimental approach to the combined clinical use of rhDNase and alpha1-PI in CF patients. Lung 2001; 179: 185-94.
3. Aitken ML, Burke W, McDonald G, Shak S, Montgomery AB, Smith A. Recombinant human DNase inhalation in normal subjets and patients with cystic fibrosis. A phase 1 study. JAMA 1992; 267: 1947-51.
4. El Hassan NO, Chess PR, Huysman MW et al. Rescue use of DNase in critical lung atelectasis and mucus retention in premature neonates. Pediatrics 2001; 108: 468-70.
5. Ramsey BW, Astley SJ, Aitken ML et al. Efficacy and safety of short term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Am. Rev. Respir. Dis. 1993; 148: 145-51.
6. Aitken ML. Clinical trials of recombinant human DNase in cystic fibrosis patients. Monaldi Arch. Chest Dis. 1993; 48: 653-6.
7. Nasr SZ, Strouse PJ, Soskolne E et al. Efficacy of recombinant human deoxyribonuclease I in the hospital management of respiratory syncytial virus bronchiolitis. Chest 2001; 120: 203-8.
8. Shak S, Capon DJ, Helmiss R, Marsters SA, Baker CL. Recombinant human DNase reduces the viscosity of cystic fibrosis sputum. Proc. Natl Acad. Sci. USA 1990; 87: 9188-92.
9. Touleimat BA, Conoscenti CS, Fine JM. Recombinant human DNase in management of lobar atelectasis due to retained secretions. Thorax 1995; 50: 1319-21.
10. Durward A, Forte V, Shemie SD. Resolution of mucus plugging and atelectasis after intratracheal rhDNase therapy in a mechanically ventilated child with refractory status asthmaticus. Crit. Care Med. 2000; 28: 560-2.
11. Voelker KG, Chetty KG, Mahutte CK. Resolution of recurrent atelectasis in spinal cord injury patients with administration of recombinant human DNase. Intensive Care Med. 1996; 22: 582-4.
12. Bryson, HM, Sorkin, EM. Dornase alfa. A review of its pharmacological properties and therapeutic potential in cystic fibrosis. Drugs. 1994; 48: 894-904.